-
BeiGene Chairman Lei Qiang Ou: After 2024, it is expected that 10 new molecules will enter the clinical JPM conference every year
Time of Update: 2023-02-01
Anti-PD-1 monoclonal antibody tislelizumab ▲BeiGene's internal R&D pipeline (Image source: Screenshot of BeiGene's speech report)▲BeiGene's internal R&D pipeline (Image source: BeiGene speech report screenshot) ▲▲Bcl-2 inhibitor BGB-11417: In the second half of 2023, a global pivotal trial in combination with zebratinib for the first-line treatment of CLL will be initiated, and data from ongoing clinical studies is expected to be available.
-
Snapped up by three multinational giants, with a market value of more than 100 billion, what did this Biotech do right
Time of Update: 2023-01-01
How critical is commercialization and capital capability for a Biotech to grow into a Biopharma?Reality tells us that it is enough for a small company to spend more than ten years, from being unknown, the CEO does not even have an office, can only work from home, into a market value of nearly 100 billion yuan, and is snapped up by multinational pharmaceutical giants.
-
The world's 15 major pharmaceutical companies gathered at the Expo for the first time, and the Chinese market became a "must fight place
Time of Update: 2022-11-26
js?cdnversion='+~(-new Date()/36e5)];The 5th China International Import Expo is in full progress, as the earliest "full" exhibition area, medical equipment and medicine health care hall is still hot this year, with an exhibition area of about 70,000 square meters, "squeezed" into more than 33 countries and regions more than 350 enterprises to participate in the exhibition.
-
Materials Today Bio: Liu Gang's team at Huazhong University of Science and Technology develops black technology for gene therapy and rapid quantitative detection of vaccine vectors
Time of Update: 2022-10-12
Gene therapy can fundamentally supplement or repair defective genes and restore the normal biological functions of healthy genes, which has incomparable therapeutic advantages. Adenoviruses or adeno-a
-
Chuangsheng Group's first clinical trial application for the treatment of solid tumors, the Gremlin1 antibody TST003, was approved by the US FDA
Time of Update: 2022-09-20
About Chuangsheng GroupChuangsheng Group is a clinically integrated biopharmaceutical company with comprehensive capabilities in biopharmaceutical discovery, R&D, process development and production.
About Chuangsheng GroupChuangsheng Group is a clinically integrated biopharmaceutical company with comprehensive capabilities in biopharmaceutical discovery, R&D, process development and production.
-
ARD: Induced antibodies to the angiotensin receptor type 1 trigger cross-species skin and lung inflammation and dermal fibrosis
Time of Update: 2022-08-12
1136 /annrheumdis-2021-222088 , et al Annals of the Rheumatic Diseases leave a message here Objective: Angiotensin receptor type 1 (AT1R, AGTR1) is a G protein-coupled receptor (GPCR) that is mainly involved in the regulation of vascular tone, vascular smooth muscle cell proliferation, extracellular matrix production and inflammation .
-
Human nose model reveals first steps of SARS-CoV-2 and RSV infection
Time of Update: 2022-03-05
"In the case of respiratory viruses, such as SARS-CoV-2 and RSV, infection begins when people inhale the virus," said corresponding author Pedro Piedra, PhD, professor of molecular virology, microbiology, pediatrics, pharmacology and chemical biology at Baylor University.
-
KPTI and Menarini Sign Exclusive License Agreement for Drug Commercialization
Time of Update: 2022-01-10
NEXPOVIO has obtained a conditional marketing authorization from the European Commission to treat adult patients with related multiple myeloma combined with dexamethasone, that is, they have received at least four previous therapies, and their disease uses at least two proteasome inhibitors and two immunizations The modulator and an anti-CD38 monoclonal antibody are incurable, and patients who showed progression of the disease in the last treatment .
-
Focusing on the future plans of the pharmaceutical equipment giants, the field of biomedicine will become a "sweet potato
Time of Update: 2021-10-01
It is foreseeable that in the process of increasing investment in the industry, upstream biopharmaceutical-related equipment will also usher in a new round of opportunities, and demand will continue to grow.
-
Hebo Pharma's new-generation anti-CTLA-4 antibody HBM4003 was approved for two clinical trials in China
Time of Update: 2021-09-19
Hebo Pharmaceutical recently announced that the National Medical Products Administration (NMPA) of China approved its new generation of HBM4003 anti-CTLA-4 fully human monoclonal heavy chain antibody and PD-1 antibody for the treatment of advanced hepatocellular carcinoma (HCC) and other solid tumors Clinical trial application for patients, and clinical trial application for HBM4003 and PD-1 antibody combined treatment of advanced neuroendocrine tumor/carcinoma (NET/NEC) and other solid tumor patients .
-
Cinda Biotech declares that the first domestic SIRPα antibody CD47 pathway has deployed 3 new drugs
Time of Update: 2021-09-11
Author: Plus OneOn September 8, Cinda Biotech declared a new type of anti-SIRP-alpha antibody IBI397 (Alector R&D code: AL008) .
Domestic CD47 antibody drug development pattern (Insight)Cinda has already deployed 3 products for CD47-SIRPα, including CD47 monoclonal antibody IBI188 (letaplimab) and PD-L1/CD47 double antibody IBI322.
-
The mutant strain "Yota" that first appeared in New York has a higher mortality rate
Time of Update: 2021-09-05
Compared with the new coronavirus mutant strain "Yota" first discovered in New York, USA in November 2020, it has greater infectivity and immune escape tendency, and can increase the mortality rate of elderly infected persons by 62%-82% .
-
Innovative psoriasis therapy is expected to be approved for IL-17A/F dual inhibitors, supported by EU CHMP
Time of Update: 2021-08-08
Reference materials:[1] UCB Receives Positive CHMP Opinion Recommending Approval of BIMZELX[®*] (bimekizumab) in the EU for the Treatment of Adults with Moderate to Severe Plaque Psoriasis.
Retrieved June 25, 2021, from https:// /stories-media/Press-Releases/article/UCB-Receives-Positive-CHMP-Opinion-Recommending-Approval-of-BIMZELX-bimekizumab-in-the-EU-for-the-Treatment-of-Adults-with-Moderate -to-Severe-Plaque-Psoriasis
-
Henlius and Runxin Biotech reached an exclusive license cooperation on BRAF V600E inhibitor
Time of Update: 2021-07-12
It is expected to become a Best-in-Class BRAF V600E small molecule inhibitor, and the target product has the potential to compete with Henlius' EGFR , PD-1 target monoclonal antibody products have a synergistic effect, creating a better differentiated and innovative product portfolio in multiple cancer fields .
This cooperation will accelerate the clinical development and commercialization of our BRAF V600E inhibitor RX208 .
-
Pfizer abrocitinib and Xeljanz review delayed by FDA for 3 months
Time of Update: 2021-04-18
In addition, the FDA has extended the review period of the supplementary new drug application (sNDA) for the oral anti-inflammatory drug Xeljanz/Xeljanz XR (tofacitinib, tofacitinib) for the treatment of adult patients with active ankylosing spondylitis (AS) by 3 months.
